February 04, 2026

To,
The Manager
Listing Department,
The National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400051

Dear Sir/Madam,

Trading Symbol: ZOTA

Sub: Press Release on Zota Health Care Limited Delivers Strong Revenue Growth of 98.2% YoY in Q3FY26

With reference to the captioned subject; we, Zota Health Care Limited, are forwarding herewith enclosed a copy of press release on Zota Health Care Limited Delivers Strong Revenue Growth of 98.2% YoY in Q3FY26.

This is for your information and record.

Thanking you,

Yours faithfully,

For **Zota Health Care Limited**

Ashvin Bhagavanbhai Variya
Digitally signed by Ashvin Bhagavanbhai Variya
Date: 2026.02.04 19:22:07 +05'30'

Ashvin Variya
(Company Secretary & Compliance Officer)
Place: Surat

Encl: Press Release

Zota Health Care Limited Delivers Strong Revenue Growth of 98.2% YoY in Q3FY26

Q3FY26 Consolidated Revenues Grew to ₹ 14,295.14 lakhs: Consolidated EBITDA at ₹ 127.58 lakhs.

Davaindia Networks Expands to 2,331 Stores Nationwide

Surat, February 4, 2026: Zota Health Care Limited, one of the leading pharmaceutical companies with an aim is to provide affordable, high-quality, generic medicines predominantly for chronic conditions, in addition to proprietary medicinal, OTC, ayurvedic, cosmetic, and nutraceutical products, announced financial results for the **Third Quarter and Nine Months ended 31st December 2025.**

Q3FY26 & 9MFY26 Consolidated Financial Highlights:

Particulars (₹in Lakhs)	Quarter Ended			Nine Months ended	
	Q3FY26	Q2FY26	Q3FY25	9MFY26	9MFY25
Export Sales (SEZ)	910.80	1,095.00	829.88	2,669.94	1,956.70
Davaindia Sales	11,479.27	9,558.60	4,590.85	28,600.77	12,432.10
Domestic Sales	1,577.32	1,790.50	1,500.65	4,874.59	4,478.00
Everyday Herbal Group	327.75	450.80	291.00	1,402.92	703.20
Revenue from Operations	**14,295.14**	**12,894.90**	**7,212.38**	**37,548.22**	**19,570.00**
Gross Profit	**8,617.82**	**7,650.34**	**4,029.15**	**22,113.06**	**10,627.16**
Gross Margin %	60.28%	59.33%	55.86%	58.89%	54.30%
EBITDA	**127.58**	**795.79**	**-556.47**	**1,406.56**	**-713.32**
EBITDA Margin%	0.89%	6.17%	-	3.75%	-

As on 31st December 2025

Q3FY26 Business Highlights:

Particulars	Q3FY26			Q3FY25		
	COCO	FOFO	Total	COCO	FOFO	Total
Total No. of Davaindia stores*	1,438	893	2,331	658	697	1,355
Quarterly Footfall (lakhs)	34.31	14.2	49	15.7	11.3	27
Quarterly GMV (₹ lakhs)	₹7,923	₹4,249	₹12,172	₹3,507	₹3,161	₹6,668
Average wallets spend (₹)	₹ 231	₹ 299	-	₹ 224	₹ 279	-

As on 31st December 2025

Key Operational & Financial Highlights:

- Consolidated Revenue from Operations stood at ₹14,295.14 lakhs in Q3FY26, registering a significant YoY growth of 98.2% compared to ₹7,212.38 lakhs in Q3FY25.
- Consolidated Gross Profit stood at ₹8,617.82 lakhs, as against ₹4,029.15 lakhs in Q3FY25, reflecting a strong YoY increase of 113.9%, supported by improved scale.
- Consolidated EBITDA stood at ₹127.58 lakhs in Q3FY26, impacted by higher operating expenses linked to ongoing expansion initiatives associated with ~400+ stores under development or in a non-live stage, where manpower, rentals, and other pre-opening costs had already commenced.
- Added 276 new stores during Q3FY26 with 231 COCO & 45 FOFO stores.
- Davaindia Networks Expands to 2,331 Stores Nationwide.

- Approved the incorporation of a wholly owned subsidiary, KMHP Ventures Limited, with a paid-up capital of ₹10,00,000, to undertake the marketing and trading of pharmaceutical products, strengthening downstream capabilities.
- Subscribed to the rights issue of Davaindia Health Mart Limited (DIHML), a wholly owned subsidiary, acquiring 3,95,348 equity shares during the quarter as a part of strategic investments to support expansion of COCO stores and meet working capital requirements.

Commenting on the Q3FY26 performance, Mr. Ketan Kumar Zota, Chairman, Zota Health Care Limited said,

"Q3FY26 marked another quarter of strong execution for Zota Health Care, with the Company delivering robust top-line growth of 98% yoy driven by continued scale-up of the Davaindia store. In Q3FY26 we added 276 stores, taking our footprint to 2,331 Davaindia stores as of 31 December 2025. Sequentially, operating profit and EBITDA declined, primarily due to higher operating expenses associated with ~400+ stores under development or in a non-live stage, where manpower, rentals, and other pre-opening costs had already commenced. As a result, the Company reported consolidated operating loss of ₹44.11 lakhs, while consolidated EBITDA stood at ₹127.58 lakhs.

The successful completion of the ₹350 crore QIP further strengthens our balance sheet and provides long-term capital to accelerate the rollout of COCO stores under Davaindia, support working capital, and meet general corporate purposes while preserving strategic flexibility. We remain confident of our long-term ambition to cross 5,000 Davaindia stores across India by March 2029.

Looking ahead, our priorities are clear: to keep scaling the Davaindia network with an even tighter focus on unit economics, to drive operating efficiencies and sustained profitability, and to deepen access to affordable, high-quality generic medicines across the country. With a strengthened balance sheet, a scalable retail engine, and a disciplined execution culture, we are well positioned to create sustainable, long-term value for our customers, employees, and shareholders."

About Zota Health Care Limited:

Zota Health Care Ltd. (Zota), listed on the NSE, has been a key player in the Indian healthcare industry since 2000. Headquartered in Surat, Zota's team of over 520 professionals drives its growth and strong market presence. The company specializes in the development, manufacturing, and marketing of high-quality pharmaceutical, ayurvedic, nutraceutical, and over-the-counter products.

Zota operates through three main divisions: marketing, export, and the retail pharmacy chain. In 2017, Zota launched Davaindia, a generic pharmacy chain offering over 2,000 SKUs of quality medicines. Davaindia's strategic business model ensures efficient management of the entire product life cycle through backward and forward integration.

Zota is renowned for its innovative Research and Development team, consistently investing in pioneering healthcare solutions, reinforcing its reputation in the industry. For more information, visit: www.zotahealthcare.com

For details please contact:

Ashvin Variya	Siddesh Chawan	Ajit Mishra
Company Secretary & Compliance Officer	Ernst & Young LLP,	Ernst & Young LLP,
Zota Health Care Ltd	Investor Relations	Investor Relations
E: cszota@zotahealthcare.com	E: Siddesh.Chawan@in.ey.com	E: Ajit.J.Mishra@in.ey.com